Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.
How To Use Stock Charts To Stay Profitable And Protected
Is Sarepta Therapeutics Stock A Buy?
The IBD 50 stock has climbed more than 5% past a 146.68 entry in a first-stage consolidation, meaning it's extended and now out of a proper buy zone. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The biotech firm reported 0% earnings growth in the latest quarterly report, while sales growth came in at 63%.
Sarepta Therapeutics stock holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics and Sarepta Therapeutics are also among the group's highest-rated stocks.
